CIK 0001799788 · Non-accelerated filer<br>Smaller reporting company
Greenwich LifeSciences, Inc.
Sign in to watch- Ticker
- GLSI
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 205473709
- Phone
- 203-434-3290
- Business address
- 3992 BLUEBONNET DR, BUILDING 14, STAFFORD, TX, 77477
- 4/A Open-market buy CEO and CFO bought 3,500 shares at $12.49 ($43,715)
- 4 Open-market buy CEO and CFO bought 30,500 shares at $12.49 ($380,945)
- 4 Open-market buy CEO and CFO bought 4,100 shares at $13.03 ($53,423)
- 4 Open-market buy CEO and CFO bought 10,800 shares at $11.16 ($120,528)
- 4 Open-market buy CEO and CFO bought 12,700 shares at $11.07 ($140,589)
- 4 Open-market buy CEO and CFO bought 5,000 shares at $10.17 ($50,838)
- 4 Open-market buy CEO and CFO bought 3,500 shares at $9.11 ($31,885)
- 4 Open-market buy VP Clinical Reg Affairs bought 500 shares at $8.57 ($4,285)
- 4 Open-market buy CEO and CFO bought 2,500 shares at $7.97 ($19,925)
- 4 Open-market buy CEO and CFO bought 2,500 shares at $7.91 ($19,775)
- 4 Open-market buy CEO and CFO bought 1,000 shares at $9.07 ($9,070)
- 4 Open-market buy CEO and CFO bought 2,000 shares at $8.63 ($17,260)
- 4 Open-market buy VP Clinical Reg Affairs bought 600 shares at $8.71 ($5,226)
- 4 Open-market buy CEO and CFO bought 4,000 shares at $8.95 ($35,800)
- 4 Open-market buy CEO and CFO bought 1,000 shares at $9.48 ($9,480)
- 4 Open-market buy CEO and CFO bought 1,000 shares at $9.97 ($9,970)
- 4 Open-market buy CEO and CFO bought 2,000 shares at $10.55 ($21,100)
- 4 Open-market buy CEO and CFO bought 1,000 shares at $9.20 ($9,200)
- 4 Open-market buy VP Clinical Reg Affairs bought 250 shares at $9.49 ($2,373)
- 4 Open-market buy CEO and CFO bought 1,000 shares at $11.69 ($11,690)
Page 3 of 8 · 146 filings